CD8A and neoplasm: Hence, based on these data, we demonstrate DP Temra cells—analyzed in the tumor specimens and even in the blood samples of the patients—as a novel means for predicting the immunogenicity of tumor antigens and accordingly, CD8+ TIL counts, a reliable biomarker for successful cancer immunotherapy.